A61K 40/4255
Mesothelin [msln]
Official title: {Mesothelin [MSLN]}
A61K40/4255 (Mesothelin [msln]) appears on 181 US grants and 447 published applications in this corpus.
Search patents in A61K- Granted patents
- 181
- Published applications
- 447
- Assignees
- 156
- Inventors
- 718
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 1 | 4 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 3 |
| 2014 | 1 | 10 |
| 2015 | 6 | 10 |
| 2016 | 2 | 11 |
| 2017 | 9 | 21 |
| 2018 | 11 | 27 |
| 2019 | 16 | 32 |
| 2020 | 27 | 40 |
| 2021 | 17 | 42 |
| 2022 | 23 | 44 |
| 2023 | 19 | 46 |
| 2024 | 20 | 60 |
| 2025 | 17 | 56 |
| 2026 | 11 | 40 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Chimeric antigen receptors targeting CD127 and use thereof4 Aug 2026US 12,697,388 B2Memorial Sloan Kettering Cancer Center
- Selective stimulation of T cells in solid tumors using oncolytic viral delivery of orthogonal IL-223 Jun 2026US 12,661,401 B2The Regents of the University of California
- Combination therapy using a chimeric antigen receptor16 Jun 2026US 12,653,850 B2Novartis AG
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Light-expressing immunoresponsive cells and uses thereof1 Oct 2026US 2026/0297517 A1Memorial Sloan Kettering Cancer Center
- CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy24 Sep 2026US 2026/0286300 A1The Trustees of the University of Pennsylvania
- Anti-mesothelin (msln) single domain antibodies and therapeutic constructs17 Sep 2026US 2026/0274984 A1National Research Council of Canada
- Nucleic acid molecule comprising intracellular signaling domain and nkp30 transmembrane domain and chimeric antigen receptor comprising the same10 Sep 2026US 2026/0263515 A1Pell Bio-Med Technology Co., Ltd.
Most cited
By later US patents
- Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor113US 9,394,368 B2Novartis AG · 2016
- Chimeric antigen receptor and methods of use thereof60US 9,587,020 B2The Regents of the University of California · 2017
- Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting52US 9,272,002 B2The Trustees of the University of Pennsylvania · 2016
- Enhancing activity of CAR T cells by co-introducing a bispecific antibody40US 9,765,156 B2The Trustees of the University of Pennsylvania · 2017
- Engineering and delivery of therapeutic compositions of freshly isolated cells36US 8,450,112 B2MaxCyte, Inc. · 2013